Senior Medical Director Clinical Development Neuroscience

Arvinas is a clinical‑stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life‑threatening diseases through the discovery, development, and commercialization of therapies that degrade disease‑causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease‑causing proteins.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102 targeting LRRK2 for neurodegenerative diseases; ARV-806 targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non‑small cell lung cancers; ARV-393 targeting BCL6 for relapsed/refractory non‑Hodgkin lymphoma; ARV‑027 targeting the polyglutamine‑expanded androgen receptor, or polyQ‑AR, in skeletal muscle; and vepdegestrant targeting the estrogen receptor for patients with locally advanced or metastatic ER+ HER2– breast cancer.

On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant, an investigational, orally bioavailable PROTAC estrogen receptor degrader, for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–), ESR1‑mutated advanced or metastatic breast cancer previously treated with endocrine‑based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out‑licensing and commercialization of vepdegestrant.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical‑stage PROTAC androgen receptor protein degrader ARV‑766 for the treatment of prostate cancer. The transaction closed in May 2024.

Team Arvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform.

We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.

Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit  and connect on Linked In and X.

This role can be located at our headquarters in New Haven, CT or work with a hybrid or remote work arrangement from a location within the U.S.

Arvinas is looking for an experienced Senior Medical Director with the passion and creativity to develop great medicines for neuromuscular and neurodegenerative diseases. The ideal candidate is a physician with experience in global drug development and filing, who is enthusiastic about applying their knowledge to improve the lives of patients with neurological diseases. This individual has excellent management and leadership capabilities and is motivated to participate in and lead an innovative drug development team.

Reporting to the Executive Medical Director of Clinical Research, Neuroscience, the Senior Medical Director will be primarily responsible for the development, oversight, and execution of clinical research and development programs, including pivotal trials and filing activities. This position will serve as a key liaison between company and clinical investigators and establish credible relationships with opinion leaders, regulatory officials and other key stakeholders and partners.

The successful candidate will be ready for a career defining experience and have the passion to drive several therapeutics for serious debilitating diseases to final approval.

• Partner with discovery and biology leadership…